For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade?

OnCusp: Bing Yuan’s newco to provide bridge from innovation to MNC（by BioCentury）

Exploring new business models in the biopharmaceutical industry （by PharmCube）